<DOC>
	<DOCNO>NCT01471379</DOCNO>
	<brief_summary>Purpose : The investigator propose examine use Savella® ( Milnacipran ) treat irritable bowel syndrome ( IBS ) woman . Participants : Eligible participant meet Rome III diagnostic criterion IBS . Procedures : This study observe patient treat Savella® well patient treat placebo ( pill active drug ) . The investigator monitor compare several patient symptom relate outcome , well evaluate health relate quality life , psychological distress relate psychosocial measure determine addition Savella® improve clinical pain response well secondary outcome include quality life .</brief_summary>
	<brief_title>Milnacipran ( Savella ) Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description>Irritable bowel syndrome ( IBS ) common functional gastrointestinal disorder characterize primarily abdominal pain associate bowel dysfunction . Like many painful functional somatic syndrome ( e.g . fibromyalgia ) pathophysiology IBS include abnormal response pain dysregulation brain-body pain pathway . IBS affect 10 % population , lead reason visit gastroenterologist primary care doctor , , United States , annually accrue health care cost $ 20 billion . In practice investigator use centrally act agent treat IBS . Historically , investigator use tricyclic antidepressant base result clinical trial , include NIH fund trial desipramine . Nonetheless , agent produce side effect limit full application . More recently investigator begin use SNRIs show benefit various pain syndrome like diabetic neuropathy , fibromyalgia . The initial impression Milnacipran help improve IBS symptom global well . There need systematically determine Milnacipran 's value IBS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Meet Rome III criterion IBS red flag . Must colonoscopy within previous 5 year exclude inflammatory bowel disease Be fluent literate English Must either nonchildbearing potential agree utilize approve birth control duration study Diagnosis treatment clinically symptomatic biochemical structural abnormality GI tract within 6 month prior screen , active disease within 6 month prior screen . Any diagnosis explain abdominal pain , Clinical evidence significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematologic , neurologic , psychiatric disease may interfere subject successfully complete trial Hepatic dysfunction ( ALT [ SGPT ] AST [ SGOT ] &gt; 3 time upper limit normal ) renal impairment ( serum creatinine &gt; 2mg/dL ) Has disease affect electrolyte balance , SIADH serum Sodium le 130mmol/L Any evidence treatment malignancy ( localize basal cell , squamous cell skin cancer cancer situ resect ) within previous year Any surgery stomach , small intestine colon , exclude appendectomy A major psychiatric disorder ( DSMIIIR DSMIV ) include major depression psychosis require hospitalization last 1 year . History attempt suicide uncontrolled bipolar disorder . Currently use antidepressant psychiatric condition like major depression . Use TCA SSRI class antidepressant acceptable use specifically treatment bowel symptom patient willing taper medication Previous use Milnacipran SNRI antidepressant ( duloxetine , venlafaxine , desvenlafaxine ) A diagnosis seizure disorder A diagnosis glaucoma Currently take heparin warfarin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS</keyword>
	<keyword>Savella</keyword>
	<keyword>Milnacipran</keyword>
	<keyword>Abdominal Pain</keyword>
</DOC>